Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.

In this video, Dr. Le discusses a phase II study that found that colorectal tumors lacking the ability to repair DNA-or mismatch repair–deficient tumors-were highly responsive to checkpoint blockade with the anti–programmed death 1 (PD-1) drug pembrolizumab. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content
Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Russ Conroy
December 3rd 2025
Article

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.

FDA Approves Durvalumab Plus FLOT in Resectable Gastric/GEJ Cancers

Tim Cortese
November 25th 2025
Article

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

Roman Fabbricatore
November 17th 2025
Article

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer

Russ Conroy
November 14th 2025
Article

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.